710 reports of this reaction
2.0% of all PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM reports
#9 most reported adverse reaction
DYSPNOEA is the #9 most commonly reported adverse reaction for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, manufactured by Fresenius Kabi USA, LLC. There are 710 FDA adverse event reports linking PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM to DYSPNOEA. This represents approximately 2.0% of all 35,839 adverse event reports for this drug.
Patients taking PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 710 FDA reports for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.0% of all adverse event reports for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, making it a notable side effect.
If you experience dyspnoea while taking PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.